Treatment of neovascular age-related macular degeneration: Current therapies
Albert J Augustin, Stefan Scholl, Janna KirchhofDepartment of Ophthalmology, Klinikum Karlsruhe, GermanyAbstract: Choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) is now the leading cause of blindness and severe vision loss among people over the age of 40 in the...
Main Authors: | Albert J Augustin, Stefan Scholl, Janna Kirchhof |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-01-01
|
Series: | Clinical Ophthalmology |
Online Access: | http://www.dovepress.com/treatment-of-neovascular-age-related-macular-degeneration-current-ther-a2776 |
Similar Items
-
Pipeline therapies for neovascular age related macular degeneration
by: Sruthi Arepalli, et al.
Published: (2021-10-01) -
Progress in the treatment of neovascular age-related macular degeneration
by: Ya-Xin Wang, et al.
Published: (2021-10-01) -
Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration
by: Reem H. ElSheikh, et al.
Published: (2022-11-01) -
Radiotherapy for neovascular age-related macular degeneration.
by: Evans, JR, et al.
Published: (2010) -
Personalized Approach in Treatment of Neovascular Age-Related Macular Degeneration
by: Radina Kirkova, et al.
Published: (2022-09-01)